The Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration-Resistance Development by Plasma Exosomal miRNA Sequencing
Tianyu Guo(Electric Power Research Institute), Yong‐Jie Lu(Queen Mary University of London), Glenda Scandura(Queen Mary University of London), Lei Xu(Fudan University), Prabhakar Rajan(University College London Hospitals NHS Foundation Trust), Jiaying Lu(Ministry of Education of the People's Republic of China), Jonathan Shamash(Queen Mary University of London), Greg Shaw(University College Hospital), Xueying Mao(Ministry of Education), Constantine Alifrangis(University College London Hospitals NHS Foundation Trust), Karen Tipples(Barts Health NHS Trust), Edwina Burke(Queen Mary University of London), Alistair Grey(Barts Health NHS Trust), Ninghan Feng(Jiangnan University), Jacek Marzec(Queen Mary University of London), Elzbieta Stankiewicz(Queen Mary University of London), Daniel M. Berney(Queen Mary University of London), R.T.D. Oliver(University of Cambridge), Caitlin R. Davies(Queen Mary University of London), Wen Wang(Queen Mary University of London), Liang Wang(Fujian Women and Children Hospital), Yang Wang(University of Glasgow), Jing Jia(Jiangsu University), Thomas Powles(National Health Service), John Hines(Barts Health NHS Trust), Sakunthala C. Kudahetti(Queen Mary University of London), Manish Kohli(Mayo Clinic in Arizona)
Cited by 64
Related Papers
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
|Journal of Clinical Oncology|2018|1.1k
Characterization of human plasma-derived exosomal RNAs by deep sequencing
|BMC Genomics|2013|1.1k
Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial
|The Lancet|2005|447
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
|Journal of Clinical Oncology|1997|334